Medications

Farxiga approved to reduce risk for CKD progression

(HealthDay)—Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.

Diseases, Conditions, Syndromes

Why do minorities have higher rates of kidney failure?

A new study investigates the reasons behind higher incidences of kidney failure among US minorities. The findings will be presented online during ASN Kidney Week 2020 Reimagined October 19-October 25.

page 1 from 25